Thymosin Alpha-1 Research for Hepatitis B
An evidence-based overview of research examining Thymosin Alpha-1 in the context of hepatitis b. This page synthesizes findings from peer-reviewed literature.
Research Summary
Thymosin Alpha-1 is approved in multiple countries for chronic hepatitis B treatment. Clinical trials demonstrate enhanced response rates when combined with interferon or nucleoside analogs. The peptide enhances T-cell-mediated immune responses against HBV-infected hepatocytes. Zadaxin (thymosin alpha-1) is approved in China, Italy, and 35+ other countries for hepatitis B. It is not FDA-approved in the United States.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Thymosin Alpha-1 may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.